Medical Diagnostics – The technology can detect and identify volatile organic compounds (VOCs) in breath as early biomarkers for disease.  Blood and urine are most commonly used in diagnosis as compared to breath VOCs. In contrast to blood and urine, breath analysis is easy, specific and highly qualitative. Advantages of breath testing include its noninvasive and non-intrusive nature, and that it can be performed repeatedly without limits to amount (unlike blood), timing (unlike urine), or frequency (unlike radiography) and has no age limits (neonates to the elderly). Breath testing has the potential to be inexpensive and portable, lending itself to a wide range of settings, from the hospital to the clinic, the home, and even remote areas and developing countries. Breath testing offers the possibility of providing real-time results in point-of-care or at-home testing, and it increases the potential for personalized medicine.

Estimated yearly US market for asthma testing, monitoring and management is $15 billion, global cancer screening market is $30 billion, global diabetes testing and monitoring is $20 billion and global TB testing is $1 billion, to name a few markets.

Specialized Medical Diagnostics for Controlling Pandemics – The World Health Organization recently (February 16, 2013) urged countries to be vigilant over the spread of a potentially fatal SARS-like virus after several new cases showed up in Britain. The same medical diagnostic technology can be used to contain or limit the spread of diseases such as bird and swine flu, SARS, or bacterial infections. The technology can be used by health authorities around the world to screen passengers entering a country, on mass transportation systems (customs, security checkpoints, ticket counters, etc.) or at hospitals and doctor offices thus limiting the spread including the possibility of pandemics. The real-time test is as simple as blowing into a tube (like a breathalyzer test). No need to collect blood, send to labs for analysis and quarantine while waiting for results.

A high body count is not the only meaningful number attached to a pandemic. The potential cost of a global outbreak of the flu or some other highly contagious disease can devastate the economy. A 2009 study by economists at the Brookings Institution analyzed the direct economic impact of closing schools during a flu pandemic. Since about one-quarter of civilian workers in the United States have a child under 16 and no stay-at-home adult, closing all the nation’s K-12 schools for two weeks would result in between $5.2 billion and $23.6 billion in lost economic activity; a four-week closing would cost up to $47.1 billion dollars — 0.3 percent of GDP. In 2003, studies have estimated, the economic loss due to the SARS outbreak in East Asian of 2% of global GDP or $200 billion.

EPR-Technologies is a biomedical spinoff of the Safar Center for Resuscitation Research, University of Pittsburgh, and is committed to the preservation of human life through rapid profound hypothermia by introducing patented products for “Emergency Preservation and Resuscitation” (EPR) to save a life when standard cardiopulmonary resuscitation (CPR) fails. The Company is a Delaware registered corporation formed to commercialize specialized technology for induction of rapid profound hypothermia and delayed resuscitation developed at the Safar Center.

Over the past 10-12 years, the U.S. Army has invested $14.75 million in grants for R&D including funds for the planned early-2013 clinical trial.  The U.S. Army shares no ownership in EPR technology or patents. The emergency medical market base for the sale of EPR products to save victims’ lives following traumatic exsanguination cardiac arrest and sudden cardiac arrest (SCA) unresponsive to defibrillation is approximately 1,600 victims per day (350 trauma and 1250 SCA) in the U.S. alone. Approximately, one victim per minute. For all other industrialized nations, the number of cases of trauma and SCA victims is estimated to be 3.5-4.5 times U.S. numbers.

EPR is critical to save lives currently unrecoverable when CPR fails. EPR-Technologies utilizes the revolutionary emergency resuscitation capabilities developed by the Safar Center over the past two decades to form the basis of the technology and “know-how” for a product line to support novel, advanced, lifesaving, emergency medical procedures. EPR-Technologies is dedicated to the memory and vision of the founder of the Safar Center, Dr. Peter Safar, M.D., to advance emergency medical resuscitation capabilities in order “to save hearts and brains too good to die”. Dr. Safar was a pioneer in resuscitation research, “the father of cardiopulmonary resuscitation” (CPR) (mouth-to-mouth breathing and chest compressions), and a world leader for public access to basic resuscitation procedures. His ongoing Safar Center team and EPR-Technologies continue the dedication and work in the advanced resuscitation procedures of EPR.

EPR-Technologies, Inc. plans to introduce novel, emergency medical procedures that will support the rapid use of profound-to-ultraprofound hypothermia in previously unrecoverable patients inducing a three (3) hour state of tolerance to lack of oxygen for any cause of cardiac arrest, like massive bleeding from auto accidents, gunshot wounds and even massive heart attacks, thereby buying time for lifesaving interventions. ULTIMATELY, EPR WILL BECOME THE NEXT EMERGENCY LIFE-SAVING “STANDARD OF CARE” PROCEDURE FOLLOWING THE FAILURE OF CPR ON ANY VICTIM.

EPR PRODUCTS AND SERVICES

The Company’s products and services fall within the following EPR categories and stages for sequential training, system readiness, and emergency use as listed: (1) EPR Catheter Kits; (2) EPR Cold Energy Flush Solutions; (3)  EPR Refrigerator and Pump Systems for Hospital and Field Use; and (4) EPR Education, Training, and Certification for Physicians and Paramedics/

The initial products contained in the above EPR-Kits, EPR Cold Energy Flush Solutions, EPR Refrigerator and Pump System, and the related techniques and procedures will require FDA 501(k) pre-market notification and approval after successful EPR clinical trials.  EPR products and technology support the rapid use of profound hypothermia in previously unrecoverable patients inducing a 3+ hour tolerance to ischemia for any cause of cardiac arrest, thereby buying time for lifesaving interventions.

During this protected, hypothermic, time period, the patient has no cardiac (no heart beat), no respiratory (no breathing), and no cerebral functions. Profound hypothermia in currently unresuscitable patients followed by delayed resuscitation is our unique brand in the marketplace. EPR is currently the only alternative to death when CPR fails.